PARP1 Inhibition Alleviates Injury in ARH3-deficient Mice and Human Cells

Overview

Journal JCI Insight

Specialties Biomedical Engineering
General Medicine

Date 2019 Mar 5

PMID 30830864

Citations 27

Authors

Masato Mashimo

Xiangning Bu

Kazumasa Aoyama

Jiro Kato

Hiroko Ishiwata-Endo

Linda A Stevens

Atsushi Kasamatsu

Lynne A Wolfe

Camilo Toro

David Adams

Thomas Markello

William A Gahl

Joel Moss

Affiliations

Soon will be listed here.

Abstract

Poly(ADP-ribosyl)ation refers to the covalent attachment of ADP-ribose to protein, generating branched, long chains of ADP-ribose moieties, known as poly(ADP-ribose) (PAR). Poly(ADP-ribose) polymerase 1 (PARP1) is the main polymerase and acceptor of PAR in response to DNA damage. Excessive intracellular PAR accumulation due to PARP1 activation leads cell death in a pathway known as parthanatos. PAR degradation is mainly controlled by poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribose-acceptor hydrolase 3 (ARH3). Our previous results demonstrated that ARH3 confers protection against hydrogen peroxide (H2O2) exposure, by lowering cytosolic and nuclear PAR levels and preventing apoptosis-inducing factor (AIF) nuclear translocation. We identified a family with an ARH3 gene mutation that resulted in a truncated, inactive protein. The 8-year-old proband exhibited a progressive neurodegeneration phenotype. In addition, parthanatos was observed in neurons of the patient's deceased sibling, and an older sibling exhibited a mild behavioral phenotype. Consistent with the previous findings, the patient's fibroblasts and ARH3-deficient mice were more sensitive, respectively, to H2O2 stress and cerebral ischemia/reperfusion-induced PAR accumulation and cell death. Further, PARP1 inhibition alleviated cell death and injury resulting from oxidative stress and ischemia/reperfusion. PARP1 inhibitors may attenuate the progression of neurodegeneration in affected patients with ARH3 deficiency.

Citing Articles

An ADPRS variant disrupts ARH3 stability and subcellular localization in children with neurodegeneration and respiratory failure.

Bannister M, Bray S, Aggarwal A, Billington Jr C, Nguyen H HGG Adv. 2024; 6(1):100386.

PMID: 39580621 PMC: 11667697. DOI: 10.1016/j.xhgg.2024.100386.

ADP-ribose hydrolases: biological functions and potential therapeutic targets.

Wang J, Wang Z, Zong W Expert Rev Mol Med. 2024; 26:e21.

PMID: 39375922 PMC: 11488344. DOI: 10.1017/erm.2024.17.

Novel heterozygous variant of causes pathogenic variation in CONDSIAS.

Yan S, Ren J, Su H, Ma J, He W, Cai X Heliyon. 2024; 10(14):e32945.

PMID: 39100487 PMC: 11295978. DOI: 10.1016/j.heliyon.2024.e32945.

Regulation of β-cell death by ADP-ribosylhydrolase ARH3 via lipid signaling in insulitis.

Sarkar S, Deiter C, Kyle J, Guney M, Sarbaugh D, Yin R Cell Commun Signal. 2024; 22(1):141.

PMID: 38383396 PMC: 10880366. DOI: 10.1186/s12964-023-01437-1.

Regulated necrosis pathways: a potential target for ischemic stroke.

Ren K, Pei J, Guo Y, Jiao Y, Xing H, Xie Y Burns Trauma. 2023; 11:tkad016.

PMID: 38026442 PMC: 10656754. DOI: 10.1093/burnst/tkad016.

References

Glowacki G, Braren R, Firner K, Nissen M, Kuhl M, Reche P . The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein Sci. 2002; 11(7):1657-70. PMC: 2373659. DOI: 10.1110/ps.0200602. View

Niere M, Mashimo M, Agledal L, Dolle C, Kasamatsu A, Kato J . ADP-ribosylhydrolase 3 (ARH3), not poly(ADP-ribose) glycohydrolase (PARG) isoforms, is responsible for degradation of mitochondrial matrix-associated poly(ADP-ribose). J Biol Chem. 2012; 287(20):16088-102. PMC: 3351285. DOI: 10.1074/jbc.M112.349183. View

Moss J, Stanley S, NIGHTINGALE M, Murtagh Jr J, Monaco L, Mishima K . Molecular and immunological characterization of ADP-ribosylarginine hydrolases. J Biol Chem. 1992; 267(15):10481-8. View

Wang Y, Kim N, Haince J, Kang H, David K, Andrabi S . Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal. 2011; 4(167):ra20. PMC: 3086524. DOI: 10.1126/scisignal.2000902. View

Teng F, Zhu L, Su J, Zhang X, Li N, Nie Z . Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia. Neurochem Res. 2016; 41(7):1516-26. DOI: 10.1007/s11064-016-1864-6. View

Jiang S, Lertvorachon J, Hou S, Konishi Y, Webster J, Mealing G . Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia. J Biol Chem. 2005; 280(40):33811-8. DOI: 10.1074/jbc.M503113200. View

Mueller-Dieckmann C, Kernstock S, Lisurek M, von Kries J, Haag F, Weiss M . The structure of human ADP-ribosylhydrolase 3 (ARH3) provides insights into the reversibility of protein ADP-ribosylation. Proc Natl Acad Sci U S A. 2006; 103(41):15026-31. PMC: 1622773. DOI: 10.1073/pnas.0606762103. View

Gupte R, Liu Z, Kraus W . PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017; 31(2):101-126. PMC: 5322727. DOI: 10.1101/gad.291518.116. View

Ying W, Sevigny M, Chen Y, Swanson R . Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. Proc Natl Acad Sci U S A. 2001; 98(21):12227-32. PMC: 59796. DOI: 10.1073/pnas.211202598. View

10.

Palazzo L, Leidecker O, Prokhorova E, Dauben H, Matic I, Ahel I . Serine is the major residue for ADP-ribosylation upon DNA damage. Elife. 2018; 7. PMC: 5837557. DOI: 10.7554/eLife.34334. View

11.

Jagtap P, Soriano F, Virag L, Liaudet L, Mabley J, Szabo E . Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med. 2002; 30(5):1071-82. DOI: 10.1097/00003246-200205000-00019. View

12.

Mashimo M, Kato J, Moss J . Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases. DNA Repair (Amst). 2014; 23:88-94. PMC: 4241382. DOI: 10.1016/j.dnarep.2014.03.005. View

13.

Gahl W, Mulvihill J, Toro C, Markello T, Wise A, Ramoni R . The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine. Mol Genet Metab. 2016; 117(4):393-400. PMC: 5560125. DOI: 10.1016/j.ymgme.2016.01.007. View

14.

Schuhwerk H, Bruhn C, Siniuk K, Min W, Erener S, Grigaravicius P . Kinetics of poly(ADP-ribosyl)ation, but not PARP1 itself, determines the cell fate in response to DNA damage in vitro and in vivo. Nucleic Acids Res. 2017; 45(19):11174-11192. PMC: 5737718. DOI: 10.1093/nar/gkx717. View

15.

Donawho C, Luo Y, Luo Y, Penning T, Bauch J, Bouska J . ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007; 13(9):2728-37. DOI: 10.1158/1078-0432.CCR-06-3039. View

16.

Barkauskaite E, Brassington A, Tan E, Warwicker J, Dunstan M, Banos B . Visualization of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-glycohydrolase activities. Nat Commun. 2013; 4:2164. PMC: 3741636. DOI: 10.1038/ncomms3164. View

17.

Cohen M, Chang P . Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nat Chem Biol. 2018; 14(3):236-243. PMC: 5922452. DOI: 10.1038/nchembio.2568. View

18.

Formentini L, Arapistas P, Pittelli M, Jacomelli M, Pitozzi V, Menichetti S . Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP-1-dependent cell death. Br J Pharmacol. 2008; 155(8):1235-49. PMC: 2607208. DOI: 10.1038/bjp.2008.370. View

19.

Hong S, Dawson T, Dawson V . Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci. 2004; 25(5):259-64. DOI: 10.1016/j.tips.2004.03.005. View

20.

Andrabi S, Kang H, Haince J, Lee Y, Zhang J, Chi Z . Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med. 2011; 17(6):692-9. PMC: 3709257. DOI: 10.1038/nm.2387. View